8-K: Bio-Rad Reports Mixed Q4 and Full-Year 2023 Results, Cautiously Optimistic for 2024

Bio-Rad Laboratories reported a decrease in fourth-quarter and full-year 2023 sales, impacted by biopharma market weakness, but anticipates a gradual recovery in the second half of 2024.

Summary

• Bio-Rad Laboratories announced its financial results for the fourth quarter and full year ended December 31, 2023.
• Fourth-quarter total net sales decreased by 6.7 percent to $681.2 million compared to $730.3 million in the same period of 2022.
• On a currency-neutral basis, fourth-quarter sales decreased by 7.7 percent.
• COVID-related sales significantly declined to approximately $0.3 million in Q4 2023 from $13.4 million in Q4 2022.
• Excluding COVID-related sales, revenue decreased by 6.0 percent on a currency-neutral basis.
• Life Science segment sales saw a significant decline of 19.1 percent, or 19.9 percent on a currency-neutral basis, primarily due to lower sales of ddPCR, qPCR, and Western blotting products.
• Clinical Diagnostics segment sales increased by 5.3 percent, or 4.2 percent on a currency-neutral basis, driven by strong demand for diabetes and quality control products.
• The fourth-quarter gross margin was 53.8 percent, down from 54.4 percent in the same period of 2022.
• Net income for the fourth quarter of 2023 was $349.7 million, or $12.14 per share, compared to $827.7 million, or $27.78 per share, in the same period of 2022, primarily impacted by changes in the fair market value of equity securities.
• Full-year 2023 net sales decreased by 4.7 percent to $2,671.3 million compared to $2,802.2 million in 2022.
• On a currency-neutral basis, full-year net sales decreased by 4.1 percent.
• Full-year COVID-related sales were approximately $4 million, compared to $109 million in the previous year.
• Excluding COVID-related sales, full-year 2023 revenue decreased by 0.4 percent year-over-year on a currency-neutral basis.
• The company expects non-GAAP, currency-neutral revenue growth of approximately 1.0 to 2.5 percent and an estimated non-GAAP operating margin of approximately 13.5 to 14.0 percent for the full year 2024.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the reported revenue declines and net loss, although there is some optimism about future recovery and the company's strategic initiatives. The mixed results and cautious outlook temper any strong positive sentiment.

Positives

• The Clinical Diagnostics segment showed positive growth, with a 5.3 percent increase in net sales for the fourth quarter.
• The company is cautiously optimistic about a gradual biopharma sector recovery in the second half of 2024.
• Bio-Rad has introduced new products and technologies, including the ddPCR Microsatellite Instability (MSI) Kit and the CFX Opus Deepwell Dx Real-Time PCR System.
• The company has expanded its libraries of StarBright dyes for flow cytometry and its portfolio of antibodies for bioanalytical assays.
• Bio-Rad has partnered with Element Biosciences to deliver RNA sequencing workflow.
• The company has settled a patent dispute and entered into a cross-licensing agreement with QIAGEN N.V. relating to digital PCR technology.
• Bio-Rad has improved its sustainability rankings based on increased scores in environmental, labor, human rights, health and safety reporting and policy implementation.

Negatives

• Total net sales decreased by 6.7 percent in the fourth quarter of 2023 compared to the same period in 2022.
• The Life Science segment experienced a significant decline of 19.1 percent in net sales for the fourth quarter.
• Full-year 2023 net sales decreased by 4.7 percent compared to 2022.
• The company reported a net loss of $637.3 million for the full year 2023.
• Gross margin decreased to 53.8 percent in the fourth quarter of 2023 from 54.4 percent in the same period of 2022.
• Income from operations decreased to $95.3 million in the fourth quarter of 2023 from $118.7 million in the same period of 2022.
• Non-GAAP net income for the fourth quarter of 2023 was $89.3 million, or $3.10 per share, compared to $98.5 million, or $3.31 per share, during the same period in 2022.

Risks

• The company faces risks related to reductions in government funding or capital spending of its customers.
• Global economic and geopolitical conditions could impact the company's performance.
• The pace of the biopharma sector's recovery is uncertain.
• The company faces challenges in the macroeconomic environment in China.
• Supply chain issues could affect the company's operations.
• International legal and regulatory risks could impact the company's business.
• The company's ability to develop and market new or improved products is a risk.
• The company faces competition in its markets.
• Foreign currency exchange fluctuations could impact the company's financial results.
• Product quality and liability issues are a risk.
• The company's ability to integrate acquired companies, products, or technologies successfully is a risk.
• Changes in the healthcare industry could impact the company's business.
• Natural disasters and other catastrophic events beyond the company's control are a risk.

Future Outlook

Bio-Rad expects non-GAAP, currency-neutral revenue growth of approximately 1.0 to 2.5 percent and an estimated non-GAAP operating margin of approximately 13.5 to 14.0 percent for the full year 2024. The company anticipates a gradual biopharma sector recovery in the second half of 2024.

Management Comments

• The ongoing weakness in biopharma markets continued to impact our fourth-quarter 2023 results, which were largely in line with expectations, said Norman Schwartz, Bio-Rad's President and Chief Executive Officer.
• Shifting focus to 2024, our full-year outlook reflects ongoing execution of our corporate transformation initiatives, effective expense management, and a cautiously optimistic view of a gradual biopharma sector recovery in the second half of the year, Mr. Schwartz continued.
• We also recognize the efforts of our global employees, whose ongoing dedication and commitment to our customers' success helped us navigate the challenges of 2023.

Industry Context

The results reflect the broader challenges faced by companies in the life science and diagnostics sectors, particularly those exposed to the biopharma market. The decline in the Life Science segment aligns with the reported weakness in biopharma spending, while the growth in the Clinical Diagnostics segment indicates a more resilient demand for essential healthcare products. The company's focus on cost management and transformation initiatives is a common response to these market conditions.

Comparison to Industry Standards

• Bio-Rad's Life Science segment decline of 19.1% in Q4 is worse than some peers, such as Danaher, which reported a more modest decline in its life sciences business.
• The Clinical Diagnostics segment growth of 5.3% is in line with other diagnostics companies, such as Abbott, which have seen steady growth in their core diagnostics businesses.
• The overall revenue decline of 6.7% in Q4 is worse than some diversified healthcare companies, such as Thermo Fisher Scientific, which have shown more resilience due to their broader product portfolios.
• The company's full-year revenue decline of 4.7% is also worse than some of its peers, indicating a more significant impact from the biopharma slowdown.
• The projected non-GAAP operating margin of 13.5-14.0% for 2024 is lower than some of its more profitable peers, suggesting a need for further cost optimization.

Stakeholder Impact

• Shareholders may be concerned about the reported revenue declines and net loss, but may be encouraged by the company's outlook for 2024.
• Employees are recognized for their dedication and commitment during the challenging year.
• Customers may benefit from the company's new product introductions and technology advancements.
• Suppliers may be affected by the company's cost management initiatives.
• Creditors may be concerned about the company's financial performance but may be reassured by the company's outlook for 2024.

Next Steps

• Management will discuss the company's fourth quarter and full-year 2023 results, as well as its detailed financial outlook, in a conference call scheduled for February 15, 2024.
• The company will continue to execute its corporate transformation initiatives.
• The company will focus on effective expense management.
• The company will monitor the biopharma sector for a gradual recovery in the second half of 2024.

Key Dates

Keywords

Bio-Rad, Life Science, Clinical Diagnostics, Financial Results, Net Sales, Gross Margin, Net Income, COVID-19, ddPCR, qPCR, Biopharma, Sartorius AG, Non-GAAP, Operating Margin, Revenue Growth